NICE fails to recommend the combination of pembrolizumab and axitinib for kidney cancer on NHS
The National Institute for Health and Care Excellence (NICE) has stated that combined use of the drugs pembrolizumab and axitinib is not recommended for untreated advanced renal cell carcinoma in adults.